Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, has appointed Jean Chang, as vice president of clinical operations and Victor Adeniyi as Senior Director of CMC.
Their appointments expand Nanoscope’s clinical and chemistry, manufacturing, and controls (CMC) team, the company said in a statement.
“As we make steady progress with our clinical trials, their expertise will help support the continued advancement of our optogenetic gene therapies to restore vision in millions of people blinded by retinal diseases,” CEO Sulagna Bhattacharya said in a statement.
The company also recently announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
Adding experts in managing clinical trials, manufacturing
Chang brings more than 20 years of experience in clinical operations and project management resulting in successful clinical trials in various therapeutic areas including CNS, cardiorenal, hematology, oncology, and ophthalmology, Nanoscope said. Previously, Chang was executive director of clinical operations at Catalyst Biosciences, and senior director, clinical operations at Adverum Biotechnologies.
Adeniyi has a decade of experience in cGMP manufacturing of biologics, including cell and gene therapy, leading successful manufacturing of clinical trial materials, Nanoscope said. He previously was head of manufacturing and tech transfer at UT Southwestern Medical Center in Dallas and manufacturing expert at Novartis Pharmaceuticals. Adeniyi also has extensive experience in cGMP manufacturing while leading teams at Lonza, and Fujifilm Diosynth Biotechnologies.
Go here for more DI People news.
You’ll find a roundup of innovators to know in North Texas. DI People includes hires, leadership moves, and accolades. Send us your news here.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
From Lockheed Martin to NASA to SpaceX, Texas is a hotbed of aerospace activity. Now UT Arlington and Texas A&M want to make that hotbed even hotter—by collaborating to advance the state's aerospace defense manufacturing community.
-
In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from VERTESS, Mr. Cooper, Active Cyber, EarthX, SWK Holdings, and more. Plus, Fort Worth Mayor Mattie Parker makes an appointment to the city council's Entrepreneurship and Innovation Committee.
-
The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.
-
Dallas-based Nanoscope Therapeutics is accelerating the development of therapies that could restore sight in patients with the help of a publicly traded firm. The retinal degenerative diseases-focused biotech company announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
-
Buttram says there are "so many careers to choose from—and we're making sure Mesquite connects the best and brightest!" The city plans to do that on October 14 by holding its third annual Manufacturing Day at Vanguard High School, 4201 Faithon P. Lucas Sr. Blvd. in Mesquite. Presented by the Mesquite Business Retention and Expansion Task Force, the event aims to connect Mesquite ISD juniors and seniors—as well as Dallas College students—with local manufacturers and manufacturing careers.
